Antibody assay for the detection and treatment of liver cancer

Inventors

ALLEN, Jared • MACDONALD, Isabel • Murray, Andrea • WELBERRY, Christopher

Assignees

Freenome Ltd • Freenome Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12716896-B2

Patent

Publication Date

2026-08-25

Expiration Date


Abstract

The present invention relates to a method of detecting liver cancer in a mammalian subject by detecting an antibody in a test sample comprising a bodily fluid from the mammalian subject, wherein the antibody is an autoantibody immunologically specific for a tumour marker protein selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B, which method comprises contacting the test sample with a tumour marker antigen selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B and determining the presence or absence of complexes of the tumour marker antigen bound to autoantibodies present in the test sample where the presence of said complexes is indicative of the presence of liver cancer. Also included within the invention are corresponding methods of diagnosing and treating liver cancer in a mammalian subject, corresponding methods of predicting response to an anti-liver cancer treatment, a corresponding method of detecting an antibody in a test sample comprising a bodily fluid from a mammalian subject and kits suitable for performing methods of the invention.

Core Innovation

The disclosed methods use autoantibodies associated with MMP9, AIF1, EpCAM, and CDKN1B to detect or diagnose liver cancer in bodily-fluid samples. The claims also describe using these markers to predict response to anti-liver cancer treatment and to build serial antibody profiles. An expanded tumour marker antigen panel, antigen titration, and double-cutoff analysis are also described in the supplied summary.

The supplied partial content does not include the background section, so the problem identified there is not explicitly described in patent. The summary reports hepatocellular carcinoma studies of the antibody panels, including early-stage detection and results from combining the panel with alpha-fetoprotein. These reported findings describe assay performance but do not establish the background problem addressed by the patent.

Claims Coverage

The supplied relevant claims identify five independent claims: claims 1, 10, 25, 26, and 27. They cover liver-cancer detection and treatment, detection using multiple autoantibodies, antibody profiling, diagnosis and treatment, and prediction of treatment response.

Liver-cancer detection and treatment using the four-antigen panel

Claim 1 covers detecting autoantibody complexes associated with one or more of MMP9, AIF1, EpCAM, and CDKN1B in a bodily-fluid sample, with liver-cancer treatment administered when such complexes are detected.

Liver-cancer detection using multiple autoantibodies and an expanded panel

Claim 10 covers detecting complexes involving two or more tumour marker antigens, using a panel that includes MMP9, AIF1, EpCAM, and CDKN1B together with further tumour marker antigens, and administering liver-cancer treatment when the specified complexes are detected.

Serial antibody profiling in liver cancer

Claim 25 covers determining whether autoantibodies bind one or more antigens in the MMP9, AIF1, EpCAM, and CDKN1B panel, with repeated determinations used to build a profile of antibody production.

Liver-cancer diagnosis and treatment using autoantibodies

Claim 26 covers diagnosing liver cancer when autoantibody complexes with one or more antigens in the MMP9, AIF1, EpCAM, and CDKN1B panel are detected, followed by treatment of the diagnosed subject.

Prediction of response to anti-liver cancer treatment

Claim 27 covers assessing autoantibody binding to the MMP9, AIF1, EpCAM, and CDKN1B panel and comparing the amount of binding with a previously established relationship between binding and likely treatment outcome to predict response.

The five independent claims cover four related uses of the specified autoantibody panel: detection linked to treatment, multiple-autoantibody detection, serial antibody profiling, diagnosis and treatment, and prediction of treatment response.

Stated Advantages

The reported hepatocellular carcinoma studies describe panel sensitivities of 28.3–46.2% and specificities generally around 87–98%. Combining the antibody panel with alpha-fetoprotein is reported to increase sensitivity to 52.5–57.4%, with early-stage detection also reported.

Documented Applications

Detection and diagnosis of liver cancer, including hepatocellular carcinoma, using autoantibodies associated with MMP9, AIF1, EpCAM, and CDKN1B in bodily-fluid samples.

Use of antibody-panel results to predict response to anti-liver cancer treatment and to support treatment of a subject when the specified autoantibody complexes are detected.

Serial antibody profiling in liver cancer by building profiles of antibody production. The supplied summary also describes high-throughput autoantibody assays, antigen titration, double-cutoff analysis, and combining the panel with alpha-fetoprotein.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.